权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Ketamine vs Midazolam: Testing Rapid Relief of Suicide Risk in Depression

氯胺酮与咪达唑仑：测试快速缓解抑郁症自杀风险

基本信息

批准号：
8837538
负责人：
Michael F Grunebaum
金额：
$ 7.74万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-07-05 至 2015-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8837538
关键词：
Adrenal Glands Adverse effects Adverse event Anesthetics Antidepressive Agents Benzodiazepines Biological Bupropion Case Management Cause of Death Cessation of life Chronic Clinical Treatment Clinical Trials Cognitive Data Depressed mood Depression and Suicide Depressive disorder Dose Double-Blind Method Eligibility Determination Emergency Department patient Evidence based treatment Excitatory Amino Acid Antagonists Feeling suicidal Glutamates Goals Guidelines Hamilton Rating Scale for Depression Hour Hydrocortisone Hyperactive behavior Hypothalamic structure Impaired cognition Infusion procedures Intervention Intravenous infusion procedures Ketamine Major Depressive Disorder Measures Memory Mental Depression Midazolam Moods Neurocognitive Pain Patients Performance Pharmaceutical Preparations Pharmacotherapy Pituitary Gland Placebos Population Public Health Randomized Recruitment Activity Relative (related person)Reporting Research Safety Saline Salivary Sampling Selective Serotonin Reuptake Inhibitor Serotonergic System Signal Transduction Suicide Suicide attempt Suicide prevention Targeted Research Testing Time blind clinical care clinically relevant clinically significant cognitive testing cost depressed patient efficacy testing evidence base high risk hypothalamic-pituitary-adrenal axis improved innovation interest patient population psychosocial response sedative single episode major depressive disorder suicidal suicidal behavior suicidal patient suicidal risk suicide attempter treatment effect

项目摘要

DESCRIPTION (provided by applicant): Suicide and suicide attempts cost an estimated $33 billion annually in the U.S. and immeasurable pain and suffering. Most suicidal behavior is associated with a depressive disorder, yet medication guidelines for suicidal patients are virtually nonexistent. The evidence base is severely limited because suicidal patients are excluded from most antidepressant clinical trials. Several recent studies show rapid improvement in suicidal ideation, in as little as one hour, in depressed patients after intravenous infusion of sub-anesthetic ketamine, a glutamate antagonist and commonly used anesthetic. The improvement in suicidal ideation appears to last several days, however, depression and suicidality are usually chronic, recurring conditions. We propose a rigorous clinical trial in suicidal depressed patients to test random assignment to IV infusion of ketamine or midazolam control followed by open continuation treatment with antidepressant medication plus supportive case management. The primary goal is to test ketamine's potential anti-suicidal effects versus a similarly sedative control medication not known to reduce suicidal ideation. Exploratory aims include analysis of potential biological (salivary cortisol) and neuro-cognitive correlates as well as systematic assessment of suicidal ideation and behavior during continuation treatment. Establishing a strong anti-suicidal signal for ketamine in this high-risk population would support an innovative intervention that could change clinical care for a patient population of public healt importance. Exploratory assessment of suicidal ideation and behavior during continuation treatment could help target research on strategies to sustain the benefit of ketamine.

在美国，自杀和自杀企图每年造成的损失估计为330亿美元，带来的痛苦和痛苦是不可估量的。大多数自杀行为都与抑郁症有关，但自杀患者的药物指南实际上是不存在的。由于大多数抗抑郁药临床试验都排除了有自杀倾向的患者，因此证据基础非常有限。最近的几项研究表明，抑郁症患者在接受静脉注射后，自杀意念在短短一小时内迅速改善，输注亚麻醉剂氯胺酮，一种谷氨酸拮抗剂和常用麻醉剂。自杀意念的改善似乎持续了几天，然而，抑郁症和自杀倾向通常是慢性的，反复发作的疾病。我们建议在自杀性抑郁症患者中进行一项严格的临床试验，以测试随机分配至氯胺酮或咪达唑仑对照静脉输注，然后开放式持续抗抑郁药物治疗加支持性病例管理。主要目标是测试氯胺酮与类似的镇静对照药物相比的潜在抗自杀作用，目前尚不清楚该药物是否能减少自杀念头。探索性的目的包括分析潜在的生物学（唾液皮质醇）和神经认知相关性作为持续治疗期间自杀意念和行为的系统评估。在这一高风险人群中建立氯胺酮的强有力的抗自杀信号将支持一种创新的干预措施，这种干预措施可能会改变对公共卫生具有重要意义的患者群体的临床护理。在继续治疗期间对自杀意念和行为进行探索性评估，有助于对维持氯胺酮获益的策略进行靶向研究。